CBS probes widespread illegal online sales of unapproved Retatrutide

Summary

The CBS News segment details an investigative report on the illegal commercialization of Retatrutide, Eli Lilly's experimental triple-agonist obesity drug still in Phase 3 clinical trials and unapproved by the FDA anywhere. Reporter Daniel Gilbert describes its availability via peptide websites labeled "research use only," licensed compounding pharmacies, telehealth firms, med spas, clinics, and even Brooklyn bodegas. The broadcast highlights that many sellers display LegitScript certification, a seal intended to verify regulatory compliance, despite this violating the certifier's own rules. Gilbert notes unprecedented scale for an unapproved drug and discusses ongoing FDA warning letters, Eli Lilly lawsuits, and potential LegitScript enforcement.

Sourcing draws from CBS's own undercover purchases, website audits identifying over 80 certified businesses promoting the drug, poison control data, and interviews with the reporter. No anonymous sources are featured; the segment references primary regulatory actions and Eli Lilly statements. Throughline emphasizes erosion of FDA safeguards and risks to consumers bypassing clinical-trial protections.

Editorial Assessment

The broadcast is high-quality investigative journalism that accurately reports federal law prohibiting commercial sale or compounding of unapproved investigational drugs like Retatrutide. Claims hold up: the drug is not FDA-approved, with Lilly planning BLA submission in Q1 2027 after positive TRIUMPH Phase 3 results showing up to 28% weight loss; widespread sales via clinics and online vendors have been confirmed by multiple outlets. Viewers receive clear warnings about unverified purity, dosing, and rising adverse events. What could skew perception is the emphasis on "unprecedented" scale without full historical comparison to past peptide or compounded-drug black markets, and limited discussion of why some licensed practitioners feel Phase 3 data justifies early prescribing. Overall, it effectively highlights enforcement gaps while directing readers to the full CBS report for named examples. No major factual errors or omitted counter-evidence undermine the core narrative.